SCHEMBL6777555

SCHEMBL6777555

NC(CCSc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.44
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
SLC1A3 P43003 3/20 0.43
SLC1A1 P43005 3/20 0.43
CDC25B P30305 1/20 0.43
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 1/20 0.42
SLC15A1 P46059 1/20 0.42
LTA4H P09960 1/20 0.42
LAP3 P28838 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
GPR55 Q9Y2T6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9052172 0.92 ALDH1A1 (0.46) IDO1ALDH1A1KMT2AMEN1SLC1A3
SCHEMBL28067779 0.86 ALDH1A1 (0.47) IDO1ALDH1A1KMT2AMEN1SLC1A3
SCHEMBL6840772 0.86 ALDH1A1 (0.47) IDO1ALDH1A1KMT2AMEN1SLC1A3
SCHEMBL11210334 0.85 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1CDC25BMAPK1
SCHEMBL7445938 0.84 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1MAPK1L3MBTL1
SCHEMBL526075 0.84 MME (0.53) IDO1ALDH1A1KMT2ASLC1A3SLC1A1
SCHEMBL7751248 0.84 MME (0.53) IDO1ALDH1A1KMT2ASLC1A3SLC1A1
SCHEMBL11207419 0.84 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1CDC25BMAPK1
Hydrochloric Acid SCHEMBL28309990 0.82 MME (0.52) IDO1ALDH1A1KMT2ASLC1A3SLC1A1
Hydrochloric Acid SCHEMBL28309991 0.82 MME (0.52) IDO1ALDH1A1KMT2ASLC1A3SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed